CS MEDICA Receives "Intention To Grant" for European Patent Application Concerning CANNASEN® Psoriasis Gel, Reinforcing Leadership in CBD-infused Dermatological Innovations
Innovative Approach to Compliant Psoriasis Treatment Aims for Patent ProtectionCS MEDICA is proud to announce the receipt of an "Intention To Grant" for its patent application from the European Patent Organization (EPO), which has 39 member states[1]. This achievement enhances the protection of its innovative product, CANNASEN® Psoriasis Gel, which contains CBD. This patent discloses a novel treatment approach for psoriasis symptoms such as pain, itch, redness, scaling, and inflammation, along with the specific composition of the psoriasis gel. Psoriasis, an immune-mediated disorder,